Category: announcements

MaxVal Sponsoring and Exhibiting at Upcoming IP Counsel Cafe, CLOC, and INTA Events

Visit us at IP Counsel Cafe “Parts Unknown: Global IP in an Increasingly Connected Yet Foreign World” in Palo Alto, California on May 7 and 8, 2019.

Continue reading

MaxVal and Aistemos Extend Litigation Data Partnership

Aistemos’s patent intelligence software, Cipher, now includes MaxVal’s international patent litigation data

Continue reading

MaxVal Announces Support for USPTO’s Authentication Changes

MaxVal announces that all of our software products and services now support the USPTO’s upcoming Private PAIR changes.

Continue reading

MaxVal Publishes Advanced Landscape Report on E-Cigarettes

MaxVal’s E-Cigarettes report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract actionable and predictive information. By leveraging data sciences best practices, MaxVal has constructed an interactive report that melds different yet related data sources into a comprehensive landscape, allowing the reader to dynamically explore relationships.

Continue reading

What to Know About the USPTO Access to Relevant Prior Art Initiative

The USPTO recently announced its Relevant Prior Art (RPA) Initiative, seeking to leverage electronic resources to improve an examiner’s access to relevant information from applicant’s other related applications.  These resources may include related U.S. applications, international applications under the PCT, and counterpart foreign applications by the same applicant.

Continue reading

MaxVal Publishes Advanced CRISPR-Cas9 Report

Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research.  The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research.  The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers.

Continue reading

MaxVal Releases Next Generation Patent Prosecution and Business Decision Tool, symphony® AI

MaxVal announces symphony® AI, the most advanced patent prosecution tool available on the market. It leverages the Salesforce Lightning architecture to integrate public and private data into a unique solution that provides decision guidance, predictions, and unprecedented insight into clients’ portfolios.

Continue reading

MaxVal Releases Max-IDS™ 4.0.2

MaxVal announces the latest upgrade to its information disclosure statement software, Max-IDS, version 4.0.2.

Continue reading

MaxVal Announces symphony® 1.5 – The Latest Version of Its Intellectual Property Management System

MaxVal announces the latest upgrade to its advanced, cloud-based IP management platform, symphony®.

Since its launch in 2016, symphony® has revolutionized IP management through its innovative use of Salesforce.com’s Lightning platform, delivering the industry’s most advanced workflow and automation capabilities; all in a highly configurable, intuitive system, designed for the modern IP department.

Continue reading

Technology Landscape Study on CRISPR-Cas9

Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives.

Continue reading